Friday, 16 October 2026European Markets

ELEC.STRASBOURG And SCATEC Have A High Dividend Yield And Return On Equity In The Utilities - Renewable Industry.

Loading stream...

(vianews) - elec.strasbourg (elec.pa) is among this list of stock assets with the highest dividend rate and return on equity on the utilities - renewable industry.

financial asset price forward dividend yield return on equity
elec.strasbourg (elec.pa) €114.00 7.45% 13.75%
scatec (scatc.ol) kr67.70 2.86% 11.58%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. elec.strasbourg (elec.pa)

7.45% forward dividend yield and 13.75% return on equity

électricite de strasbourg société anonyme engages in the supply of electricity and natural gas to individuals, businesses, and local authorities in france. it is also involved in the design, construction, and operation of electrical engineering, industrial, and public lighting facilities, as well as heating networks; provision of collective catering engineering and energy renovation services; and technical management and optimization of energy installations. the company was founded in 1899 and is based in strasbourg, france. électricite de strasbourg société anonyme operates as a subsidiary of edf développement environnement sa.

earnings per share

as for profitability, elec.strasbourg has a trailing twelve months eps of €5.44.

pe ratio

elec.strasbourg has a trailing twelve months price to earnings ratio of 20.96. meaning, the purchaser of the share is investing €20.96 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.75%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, elec.strasbourg's stock is considered to be oversold (<=20).

dividend yield

according to morningstar, inc., the next dividend payment is on jun 28, 2024, the estimated forward annual dividend rate is 8.6 and the estimated forward annual dividend yield is 7.45%.

moving average

elec.strasbourg's worth is higher than its 50-day moving average of €106.25 and way higher than its 200-day moving average of €97.00.

more news about elec.strasbourg.

2. scatec (scatc.ol)

2.86% forward dividend yield and 11.58% return on equity

scatec asa, together with its subsidiaries, provides renewable energy solutions worldwide. the company operates through power production; services; and development & construction segments. it develops, builds, owns, and operates solar, wind, and hydro power plants and storage solutions. the company is also involved in the engineering, procurement, construction, operation, maintenance, and asset management of power plants. it has a total of 4.6 gw in operation and under construction. the company was formerly known as scatec solar asa and changed its name to scatec asa in november 2020. scatec asa was incorporated in 2007 and is headquartered in oslo, norway.

earnings per share

as for profitability, scatec has a trailing twelve months eps of kr-1.11.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.58%.

revenue growth

year-on-year quarterly revenue growth grew by 17.2%, now sitting on 3.4b for the twelve trailing months.

more news about scatec.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com